anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The "Self-learning group" was designed to provide a description of the goals of the course and a reading of the Atomic Habits book. In the first session, the goals of the study were explained, the basic abilities of the caregiver and the case, the games, the relationship, the main problems that the caregiver wanted to change, the "Parent Problem Checklist" to help assess the caregiver's direction in identifying their own expectations, and the caregiver's perceived barriers and difficulties. The next 8 weeks of the course are based on the parents' self-study progress, and the study provides an online platform or a paper sheet to keep track of the self-study process and to contact the researcher at any time if there are any unexpected situations or problems. The record sheets were returned at the end of the 8-week period, and the self-study group received a face-to-face consultation at the end of the post-test.
Transplantation with hematopoietic cells has been used for a wide variety of blood disorders, but also for diseases like solid organ cancers. Interestingly, women who have had bone marrow transplants have been found to have donor tissue in their endometrium, which raises the possibility of cellular therapies using bone marrow derived cells for gynecologic indications. Donor engraftment does not appear to occur when transplantations were performed with stem cells collected from peripheral blood of the donor. Therefore, the subtype of cells from the bone marrow responsible for engraftment is not yet known, nor is the ideal transplantation regimen known.

The immediate aim of this tissue procurement protocol is to obtain endometrial (uterine) stem cells from many human volunteers in order to examine the biological properties of those cells. We will collect tissue from 3 primary groups of patients: normal controls, patients with rare diseases or reproductive disorders, and patients who have undergone hematopoietic stem cell transplant. Each volunteer will undergo an endometrial biopsy during an office visit. The endometrial tissue will then be studied for a better understanding of their biological properties, growth and differentiation. One specific area of interest is to study how hematopoietic transplantation impacts endometrial cell function. These endometrial cells will be analyzed in-depth in the laboratory to determine if they came from the donor or recipient, and if so, which specific populations of cells. Hematologic pre-transplant conditioning information will be correlated with these research studies to identify factors that may assist with the understanding of adult endometrial stem cell biology.
PURPOSE:To obtain a reagent having high S/N and high measurement accuracy with a lipid having a small mol.wt. as a starting point by bringing a phospholipid and/or glycolipid having an amino group into reaction with an amino acid in which the amino group is protected by a Boc group. CONSTITUTION:The phospholipid and/or glycolipid having the amino group is brought into reaction with the amino acid in which the amino group is protected by the Boc group to introduce the amino acid residue to the amino terminal of the phospholipid and/or glycolipid having the amino group. The Boc group is then removed and a crosslinking group is introduced to the amino terminal of the amino acid residue phospholipid and/or glycolipid. Liposome is further synthesized from the crosslinking group - amino acid residue phospholipid and/or glycolipid and labeling material and at least part of antigens or antibodies are immobilized to the resultant liposome. For example, a dipalmitoyl phosphatidyl ethanolamine is used as the phospholipid and/or glycolipid having the amino group and, for example, an epsilon-aminocaproic acid is used for the amino acid.
Haploidentical donor-derived NK cell infusion, Epratuzumab 360 mg/m\^2 once a day by vein (IV) on Day -4, Day -1 and Days 3, 6, 10, 13 and 17, and low-dose interleukin-2 (IL-2) Subcutaneous injections three times a week for 9 doses on Days 0 to 21; Fludarabine 25 mg/m\^2 once a day IV on Day -6 through Day -2 over 30 minutes; Cyclophosphamide 60 mg/kg once a day IV on Days -5 and -4 over 2 hours. Mesna 12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
Six placebo capsules containing microcrystalline cellulose consumed daily during 12 weeks. Two capsules consumed with each of the three main meals.
For Nonsmall Cell Lung Cancer (NSCLC) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour every 3 weeks (a study medication cycle) and up to 4 study medication cycles throughout this study. For Squamous Cell Carcinoma of the Head and Neck (SCCHN) Docetaxel (either Group I or Group II) 60 mg/m2 will be administrated by intravenous infusion for 1 hour followed by cisplatin 60 \~ 75 mg/m2 for 1-3 hours or based on the general practice of the site every 3 weeks and up to 4 study medication cycles throughout this study.
The skin is a physical and immunological barrier to the external environment. Its large surface area is colonized by diverse communities of microorganisms, including bacteria, viruses, fungi, and Demodex species mites. These microorganisms and their genetic material together create the skin microbiome. Physiologic and anatomic properties of skin sites create biogeographical habitats (dry, moist, and sebaceous) where distinct microbiota communities reside. Although, in general, the composition of these habitats is maintained from person to person, the skin microbiome of an individual also has unique microbial features. Dysbiosis occurs when the normal abundance, composition, or location of the microbiota is changed, most notably there is a decrease in flora diversity. Certain skin diseases, including atopic dermatitis, rosacea, and psoriasis are associated with cutaneous dysbiosis, and even disruption of the gut microbiota. Studies have shown that current treatments for these dermatologic conditions can alter/stabilize the skin microbiome, and there is emerging research detailing the impact of prebiotics, probiotics, and postbiotics on these conditions. Although clinical guidelines do not currently exist, clinical studies support the safety and possible benefits of using topical prebiotics and postbiotics and oral probiotics for a variety of skin conditions. Until such guidelines exist, utilizing carefully designed clinical studies to inform clinical practice is recommended.
The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. 

10.1 Acute Overdosage   
Manifestations of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include tachycardia, arrhythmia, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Overdosage of pharmacologically similar compounds has resulted in fatal poisoning usually terminates in convulsions and coma.   
Management of acute phentermine hydrochloride intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard. Acidification of the urine increases phentermine excretion. Intravenous phentolamine (Regitine®, CIBA) has been suggested on pharmacologic grounds for possible acute, severe hypertension, if this complicates overdosage. 

10.2 Chronic Intoxication   
Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia. See Drug Abuse and Dependence (9.3). 

Please review the manufacturer's complete drug information available from the FDA at www.fda.gov   
Permanent Link: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b963f7bb-fa65-4e28-81c9-282fbe70a6a6
BACKGROUND: The preservation of the left colic artery (LCA) has emerged as a preferred approach in laparoscopic radical resection for rectal cancer. However, preserving the LCA while simultaneously dissecting the NO.253 lymph node can create a mesenteric defect between the inferior mesenteric artery (IMA), the LCA, and the inferior mesenteric vein (IMV). This defect could act as a potential "hernia ring," increasing the risk of developing an internal hernia after surgery. The objective of this study was to introduce a novel technique designed to mitigate the risk of internal hernia by filling mesenteric defects with autologous tissue.
METHODS: This new technique was performed on eighteen patients with rectal cancer between January 2022 and June 2022. First of all, dissected the lymphatic fatty tissue on the main trunk of IMA from its origin until the LCA and sigmoid artery (SA) or superior rectal artery (SRA) were exposed and then NO.253 lymph node was dissected between the IMA, LCA and IMV. Next, the SRA or SRA and IMV were sequentially ligated and cut off at an appropriate location away from the "hernia ring" to preserve the connective tissue between the "hernia ring" and retroperitoneum. Finally, after mobilization of distal sigmoid, on the lateral side of IMV, the descending colon was mobilized cephalad. Patients'preoperative baseline characteristics and intraoperative, postoperative complications were examined.
RESULTS: All patients' potential "hernia rings" were closed successfully with our new technique. The median operative time was 195 min, and the median intraoperative blood loss was 55 ml (interquartile range 30-90). The total harvested lymph nodes was 13.0(range12-19). The median times to first flatus and liquid diet intake were both 3.0 days. The median number of postoperative hospital days was 8.0 days. One patient had an injury to marginal arterial arch, and after mobolization of splenic region, tension-free anastomosis was achieved. No other severe postoperative complications such as abdominal infection, anastomotic leakage, or bleeding were observed.
CONCLUSIONS: This technique is both safe and effective for filling the mesenteric defect, potentially reducing the risk of internal hernia following laparoscopic NO.253 lymph node dissection and preservation of the left colic artery in rectal cancer surgeries.
BACKGROUND: Mediastinitis and sternal osteitis are critical complications in cardiac surgery. Cases of these complications caused by Mycoplasma hominis are extremely rare.
CASE PRESENTATION: We present a case of mediastinitis and sternal osteitis caused by M. hominis infection following ascending aortic replacement surgery. Whole gene sequencing analysis suggested the genitourinary tract as the most likely source of this M. hominis infection. Successful infection control was achieved through a regimen of moxifloxacin treatment. Additionally, a notable correlation was observed between serum levels of interleukin-6 and M. hominis infection.
CONCLUSIONS: The significance of M. hominis as a potential cause of postoperative infection in cardiac surgery is still not fully recognized. Special attention should be paid to patients with bacteriologically negative infections, as M. hominis should not be disregarded, despite its rarity.
The slow released anticancer injection containing tyrosine kinase inhibitor and/or platinum compound consists of slow released microsphere and solvent. The slow released microsphere includes effective anticancer components of tyrosine kinase inhibitor and/or platinum compound and slow releasing supplementary material, and the solvent is common solvent or special solvent containing suspending agent. The suspending agent is carboxymethyl cellulose, etc. and has viscosity of 100-3000 cp at 20-30 deg.c. The slow releasing supplementary material is selected from p(LAEG-EOP), p(DAPG-EOP), p(BHET-EOP/TC), etc. The anticancer composition may be also prepared into slow released implant, and the released injection and slow released implant may be injected or set in tumor for slow releasing to maintain effective medicine concentration for over 50 days, and has obviously lowered systemic reaction on the medicine and capacity of enhancing the chemotherapeutic and radiotherapeutic effect.
The invention discloses a preparation method of powder for clearing away heat and toxic materials of livestock and poultry. The preparation method is characterized in that by weight, 60 parts of isatis roots, 60 parts of milkvetch roots, 30 parts of herba epimedii and 10-16 parts of rheum officinale are smashed, screened and mixed to be uniform to obtain the powder. The formula is improved, and the rheum officinale used for achieving purgation, removing indigestion and purging fire for removing toxin is added; diarrhea and dysentery of animals are not caused, and remarkable treatment effect is achieved on fever symptoms of animals. Body energy and vigor of animals are ensured; in addition, the medicine has the immunity enhancing effect, the anti-virus capability can be significantly improved, and the virosis infection rate of animals is significantly lowered. Good growth tendency of animals is kept. The using amount of antibiotics is reduced, and the problems that livestock and poultry produce drug resistance and immunity is lowered are avoided. Clinical medication is convenient, and the breeding cost is reduced.
The purpose of this study is to develop a database of normative and adaptive control strategies for human motion. Volunteers will serve as subjects after they complete a neuromusculoskeletal screening exam. Subjects will be asked to perform one or more tasks related to the execution of activities of daily living such as: walking on the ground, walking on a treadmill, quiet and perturbed standing, stair ascent and descent, turning and jumping, cycling, elliptical training, and isolated upper and lower extremity limb movements or trunk movements. The subjects movement patterns will be recorded using a three-dimensional motion tracking system. Motion data will be analyzed using a rigid body six degree-of-freedom approach when applicable. Temporal/spatial, kinematic, kinetic, and surface electromyographic variables will be collected and calculated. When only temporal-spatial parameters are of interest, an instrumented portable walkway system may be used.

Many factors affect the ability to move. The ones we are mainly interested in investigating include muscle weakness, spasticity, and dynamic balance. To quantify strength or spasticity, a force transducer is needed such as a Biodex isokinetic dynamometer which is a standard rehabilitation assessment and training device, or a more simple handheld dynamometer can be used that the person presses against as force is recorded. For the spasticity tests, a person or a machine such as the Biodex moves a joint through an arc of motion (e.g. elbow, knee, or ankle) at a range of speeds from 5-240 degrees per second while resistance to motion is being recorded or graded subjectively. EMG and joint position may be collected simultaneously during the passive movements. The dynamic balance tests will be performed on a force plate or using a clinical balance testing device, the Equitest, by Neurcom. To determine if electrical stimulation (ES) improves limb movement, walking, and balance, a FDA-cleared device (LG-8TM FDA 510K 4 Channel TENS/EMS Unit, LGmedsupply.com) may be used in patients who have some gait dysfunction in their lower extremities. Only persons with central nervous system injuries who have an abnormal gait pattern will be given the opportunity to use this device. The device delivers individually programmed ES to aid in muscle function of the hip, knee or ankle.

Patient groups will be identified clinically or statistically. Group means and standard deviations will then be computed. It is hoped the database developed may serve as a tool by which individual patient data may be compared in order to facilitate the diagnosis and optimize the treatment and clinical outcome of patients with movement related problems.

An over ground harness system may be used for some of the over ground or instrumented gait and balance assessments if there is concern that the patient is too weak or unbalanced and therefore may trip or fall during the activity, or to help facilitate more normal patterns by decreasing the load borne by the trunk and/or legs.
The present invention relates to a novel oral cavity medicine which is an orally taken medicine with durable effect. The present invention is characterized in that controlled release or slow release tablets, particles, pills, medicinal powder, etc. are sealed in a filter bag so that medicine blocks and medical powder which are blown out when the medicine is orally taken can be prevented from being swallowed, and salivary flush force can be reduced. Thus, the present invention has durable effect which can last for more than a plurality of days, once treatment is facilitated, and the problem that orally administered medicines only have short effect is solved. When sputum enters the bag, the medicine is dissolved, soaked out, immediately generates therapeutic effect on local parts, such as the oral cavity or the throat, or rapidly generates systemic effect through being absorbed by sublingual mucous membrane, etc. A patient taking the medicine neither has a foreign matter feeling nor is hindered from speaking, and the medicine can be taken out temporarily when the patient eat or gargle before being placed back.
Once a participant has completed the questionnaires, that participant will be randomly assigned to either an immediate NAMI Basics class (Wave A), or an 8-week delay (Wave B) condition. Those in the immediate condition will be assigned to take the next available NAMI Basics class. Participants in both groups will be assessed at three time points. Participants in the immediate Basics group (Wave A) condition will be assessed pre-class, post-class, and 6 months after class has ended.
Disclosed is a technique about a method for adjusting a difficulty level of a training digital content. The method for adjusting a difficulty level of a training digital content comprises: a training content preparing process of preparing training content including a plurality of events; and a difficulty level adjusting process of adjusting or keeping a difficulty level of the training content according to a training result of an examinee who performs the training content or stopping the execution of the training content performed by the examinee. The training content is prepared by dividing the plurality of events into n events (n is an integer greater than 1) as a unit. According to the training result of the examinee for a unit (hereinafter referred to as a first unit) performed by the examinee, the difficulty level adjusting process determines a difficulty level of a unit (hereinafter referred to as a second unit) following the first unit or stops the execution of the second unit performed by the examinee. The technique disclosed herein defines difficulty level variables and adjusts a dynamic difficulty level in real-time through the determination of training attitude in addition to a training result of an examinee so that a user who finds the current level of training difficult can perform the training content until the end through the adjustment of the difficulty level and a user who fines the current level of training easy is presented with questions having a higher difficulty level so as to increase interest and achievement in performing the training content. Accordingly, the present invention has the effect of increasing participation in the training content.
A device for the controlled release of an active material into an aqueous medium comprises a water- soluble body having a plurality of cavities therein containing the active material. The body may be enclosed in a casing of a material having a relatively low dissolution rate and provided with means (e.g. an aperture) whereby a portion of the body can be exposed to dissolving attack by the aqueous medium. The body is so constructed that the cavity contents are released sequentially and at a predetermined rate. The water-soluble body is made of a water-soluble glass, the cavities comprising an array of end-blocked capillaries of such glass, encased in a water-insoluble glass casing having an aperture therein. The device is for use as an implant or bolus for extended administration of a pharmaceutically active agent to animals. The agent may be a drug or curative medicine, a hormone, an insecticide, a nematocide, a fungicide, an algicide, a bacteriocide, a molluscicide, a spermicide, or a mixture of these agents.
The present invention provides TIGIT monoclonal antibodies, particularly humanized monoclonal antibodies that specifically bind to TIGIT with high affinity. The invention also provides functional monoclonal antibodies having cross-reactivity to TIGIT in humans, cynomolgus monkeys and mice. The invention also provides amino acid sequences of the antibodies of the invention, cloning or expression vectors, host cells and methods for expressing or isolating the antibodies. Epitopes of the antibodies were identified. Therapeutic compositions comprising the antibodies of the invention are also provided. The invention also provides methods of using anti-TIGIT antibodies to treat cancer and other diseases.
Taurolidine be held in each infusion central venous catheter lumen with a volume that varies in accordance with the lumen via the catheter. The solution will be administered every day while the patient is on break from parenteral nutrition, and the catheter solution residence time will be the same time of the break from parenteral nutrition. Taurolidine infusion will be used TaurolockTM with ampoule presentation containing 3 ml.
We will develop a nomogram for warfarin dosing that uses rapid turnaround genetic testing and monthly nomogram modification (if necessary) to achieve effective and safe warfarin induction and maintenance. More than 70% of the time, we will maintain warfarin naïve patients within the target therapeutic range. The percent of time in the therapeutic range will be analyzed beginning 2 weeks after initiation of warfarin. Analyses will be stratified by the indication for anticoagulation.
Participants assigned to TAU will receive usual care at San Francisco VA Health Care System (referral to Tobacco Cessation Clinic and the VA Telequit Quitline) over the 5 weeks. They will also be offered a 5-week supply of medication for Tobacco Use Disorder (TUD).
Participants in the control group will receive a simplified version of the app with sleep hygiene (SH) instructions and will be required to complete daily electronic sleep diaries for the next 6 weeks. The SH condition will utilize the same application and entail the same daily and weekly logs, but with the didactic material replaced by detailed education about SH strategies. Each week, participants will be asked to complete a brief assessment of their experiences from the previous week and their current insomnia severity.
An electronic apparatus and method for medical examination of human body using haptics is provided. The electronic apparatus controls a first head-mounted display to render a 3D model of an anatomical portion of the body of a human subject. The rendered 3D model includes a region corresponding to defect portion in the anatomical portion. The electronic apparatus transmits a touch input to wearable sensor in contact with the anatomical portion. Such an input corresponds to a human touch on the region of the rendered 3D model. The electronic apparatus receives, based on the touch input, bio-signals associated with the defect portion via the wearable sensor. The bio-signals include physiological signals and somatic sensation information associated with the defect portion. As a response to the human touch, the electronic apparatus controls a wearable haptic device to generate a haptic feedback based on the received set of bio-signals.